Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
pubmed:
13
9
2022
medline:
12
10
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Until recently, metastatic uveal melanoma was associated with essentially uniform fatality within months. However, recent developments in screening, improved understanding of the genetic underpinnings of metastatic disease, and pivotal medication approvals have improved the disease's rate of fatality. Routine implementation of genetic testing at the time of primary tumor treatment via gene expression profiling or chromosomal analysis has identified patients who are at high risk for metastatic disease. Enhanced screening with imaging directed at the liver and lungs has allowed for identification of early disease and lower tumor burden. Significant work on improved liver directed therapy along with systemic chemotherapy and immunotherapy has improved life expectancy. The first systemic immunotherapy specifically for metastatic uveal melanoma was approved this year. This medication, tebentafusp, is likely to improve life expectancy for all patients with metastatic melanoma assuming they have appropriate human leukocyte antigen (HLA) markers. Multiple clinical trials with novel immunotherapeutic agents are promising as well. The prognosis for patients with uveal melanoma is far better than ever before because of recent developments in the understanding and treatment of metastatic disease.
Identifiants
pubmed: 36094043
doi: 10.1097/ICU.0000000000000905
pii: 00055735-202211000-00018
doi:
Substances chimiques
Recombinant Fusion Proteins
0
tebentafusp
N658GY6L3E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
585-590Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Reichstein DA, Brock AL. Radiation therapy for uveal melanoma: a review of treatment methods available in 2021. Curr Opin Ophthalmol 2021; 32:183–190.
Reichstein D. New concepts in the molecular understanding of uveal melanoma. Curr Opin Ophthalmol 2017; 28:219–227.
Seedor RS, Eschelman DJ, Gonsalves CF, et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12:117.
Valsecchi ME, Orloff M, Sato R, et al. Adjuvant sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls. Ophthalmology 2018; 125:210–217.
Karlsson J, Nilsson LM, Mitra S, et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun 2020; 11:1894.
Cai L, Paez-Escamilla M, Walter SD, et al. Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma. Am J Ophthalmol 2018; 195:154–160.
Schefler AC, Kim RS. Recent advancements in the management of retinoblastoma and uveal melanoma. Fac Rev 2021; 10:51.
Schefler AC, Skalet A, Oliver SC, et al. Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling. Melanoma Manag 2020; 7:MMT37.
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol 2018; 10:1758834018757175.
Hoppener DJ, Grunhagen DJ, Eggermont AMM, et al. An overview of liver directed locoregional therapies. Surg Oncol Clin N Am 2021; 30:103–123.
Zane KE, Cloyd JM, Mumtaz KS, et al. Metastatic disease to the liver: locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12:725–745.
Carle X, Gastaud L, Salleron J, et al. Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres. Bull Cancer 2020; 107:1274–1283.
Williams SJ, Rilling WS, White SB. Quality of life and cost considerations: Y-90 radioembolization. Semin Intervent Radiol 2021; 38:482–487.
Lionberg A, Nijhawan K, Navuluri R, et al. Hybrid angiography-CT for transarterial radioembolization: a pictorial essay. Abdom Radiol (NY) 2021; 46:2850–2854.
Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB (Oxford) 2022; 24:152–160.
Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013; 119:3687–3695.
Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One 2015; 10:e0118564.
Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122:3344–3353.
Heppt MV, Amaral T, Kahler KC, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multicenter study. J Immunother Cancer 2019; 7:299.
Najjar YG, Navrazhina K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer 2020; 8:
Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol 2021; 39:599–607.
Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, a TCR/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2020; 26:5869–5878.
Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 2021; 385:1196–1206.
Lowe KL, Cole D, Kenefeck R, et al. Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treat Rev 2019; 77:35–43.
Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol 2020; 38:3947–3970.
Lutzky J, Feun LG, Magallanes N, et al. NCT04552223: a phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094). J Clin Oncol 2021; 39:TS9590–TS19590.
Rago F, Elliott G, Li A, et al. The discovery of SWI/SNF chromatin remodeling activity as a novel and targetable dependency in uveal melanoma. Mol Cancer Ther 2020; 19:2186–2195.
Gottschalk A, Agresta S, et al. Foghorn Therapeutics. Foghorn Research and Development Corporate Overview. Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond. Webinar. 2021.
Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res 2016; 22:1234–1242.
Group AP. Advancing Therapies that Restore Apoptosis (Corporate Deck); 2021.
Tolcher A, Reeves JA, McKean M, et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. In ASCO Annual Meeting, J Clin Oncol 2021; 39:2506–2506.
Wire B, Patel S, Carvajal R, Orloff M. TriSalus life sciences announces first patient enrolled in PERIO-01 clinical trail to evaluate delivery of SD-101 via pressure-enables drug delivery in uveal melanoma liver metastases; 2021.
McKean M, Carvajal R, Maurer M, Hata Y. Darovasertib (IDE196) Monotherapy Clinical Data Update in Solid Tumors. Darovasertib shows Efficacy as Monotherapy in MUM and GNAQ/11 Skin Melanoma; Darovasertib + Binimetinib Combination Therapy; Darovasertib Clinical Development Plan. Ideaya Biosciences Investor Day. Improving lives through transformative precision medicine. 2021.
Triozzi PL, Singh AD. Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol 2014; 1:54–62.
McLean IW, Berd D, Mastrangelo MJ, et al. A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. Am J Ophthalmol 1990; 110:522–526.
Salmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998; 24:127–130.
Lane AM, Egan KM, Harmon D, et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009; 116:2206–2212.
Richtig E, Langmann G, Schlemmer G, et al. Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma. Ophthalmologe 2006; 103:506–511.
Voelter V, Schalenbourg A, Pampallona S, et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008; 18:220–224.
Binkley E, Triozzi PL, Rybicki L, et al. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. Br J Ophthalmol 2020; 104:524–528.
Surriga O, Rajasekhar VK, Ambrosini G, et al. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther 2013; 12:2817–2826.
Van der Velden P, de Lange M, Versluis M, Luyten G, Jager M. Leiden uveal melanoma group. Preclinical analysis of Crizotinib in MAPK independent uveal melanoma metastases. In ARVO Annual Meeting. Investigative Ophthalmology & Visual Science; 2013.
Khan S, Lutzky J, Shoushtari AN, et al. Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. J Clin Oncol 2020; 38:10075–110075.
Sato T, Orloff MM, Valsecchi ME, et al. A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma. J Clin Oncol 2020; 38:e22059–e122059.
Rapisuwon S, Patel SP, Carvajal RD, et al. Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma. J Clin Oncol 2019; 37:TS9604–TS19604.